Agenus News and Resources

Agenus Inc. has signed definitive agreements with Zydus Lifesciences Ltd. to advance the clinical development and manufacturing of its immuno-oncology candidates, botensilimab and balstilimab (BOT/BAL). The collaboration includes a $75 million upfront payment to Agenus for the transfer of its biologics CMC facilities